Shares of Oculus Innovative Sciences Inc. (NASDAQ:OCLS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $7.00 for the company, according to Zacks. Zacks has also given Oculus Innovative Sciences an industry rank of 93 out of 265 based on the ratings given to related companies.
Separately, Maxim Group reaffirmed a “buy” rating and set a $7.00 price target on shares of Oculus Innovative Sciences in a report on Thursday, August 11th.
Shares of Oculus Innovative Sciences (NASDAQ:OCLS) traded down 0.23% during midday trading on Monday, hitting $4.33. 3,982 shares of the stock were exchanged. Oculus Innovative Sciences has a 1-year low of $3.57 and a 1-year high of $7.15. The firm has a 50-day moving average of $4.13 and a 200-day moving average of $4.52. The company’s market capitalization is $18.19 million.
Oculus Innovative Sciences (NASDAQ:OCLS) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.61) earnings per share for the quarter. Oculus Innovative Sciences had a negative net margin of 68.29% and a negative return on equity of 108.93%. On average, equities analysts expect that Oculus Innovative Sciences will post ($2.04) EPS for the current year.
Oculus Innovative Sciences Company Profile
Oculus Innovative Sciences, Inc is a specialty pharmaceutical company, which focuses on identifying, developing and commercializing therapies to manage the lives of patients with dermatologic diseases or conditions. The Company’s products treat certain topical skin diseases, including acne, atopic dermatitis, scarring, infections, itch, pain and inflammatory responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oculus Innovative Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculus Innovative Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.